FDA
-
-
-
-
-
-
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
-
-
-
-
-
-
-
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and
-
-
-
-
-
-
-
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
-
-
-
-
-
-
-
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma
-
-
-
-
-
-
-
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
-
-
-
-
-
-
-
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
-
329,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

